The ASCO Post (@ascopost) 's Twitter Profile
The ASCO Post

@ascopost

News and views from the world of clinical oncology and hematology

ID: 96994334

linkhttp://WWW.ASCOPOST.COM calendar_today15-12-2009 14:48:51

34,34K Tweet

61,61K Takipçi

4,4K Takip Edilen

The ASCO Post (@ascopost) 's Twitter Profile Photo
The ASCO Post
@ascopost

2 months ago

FDA approves pembrolizumab for resectable, locally advanced HNSCC based on KEYNOTE‑689. Led by Dr. Ravindra Uppaluri Ravi Uppaluri, MDPhD, the study showed a 30% drop in recurrence risk. Full details from The ASCO Post: ascopost.com/news/june-2025… #HNSCC #Oncology

FDA approves pembrolizumab for resectable, locally advanced HNSCC based on KEYNOTE‑689. Led by Dr. Ravindra Uppaluri <a href="/DrUppaluri/">Ravi Uppaluri, MDPhD</a>, the study showed a 30% drop in recurrence risk. Full details from The ASCO Post: ascopost.com/news/june-2025… #HNSCC #Oncology